Pfizer Research Grant Request for Proposals
Pfizer Inc.'s grant supports research into novel brentuximab vedotin-based combinations for AITL and PTCL-NOS, aiming to address key clinical and scientific gaps in lymphoma treatment.
Funder: Pfizer Inc.
Due Dates: August 26, 2026 (Submission deadline, 23:59 EST)
Funding Amounts: Up to $500,000 per project; 1–2 projects funded; max duration 3 years
Summary: Supports investigator-sponsored clinical studies of brentuximab vedotin-based novel combinations in AITL and PTCL-NOS to address key clinical and scientific gaps.
Description
This competitive research grant from Pfizer Inc. is designed to advance interventional, investigator-sponsored research on brentuximab vedotin in novel combination therapies for angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). The program seeks to generate robust clinical evidence by supporting studies that address key clinical and scientific gaps, with a focus on evaluating the safety and efficacy of brentuximab vedotin-based combinations with existing PTCL treatments. The ultimate goal is to deepen understanding of disease biology and mechanisms of action, contributing to improved patient outcomes in hematologic oncology.
